Granulocyte Colony-Stimulating Factor Lenograstim
Neoplasm
Sanofiprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
890 Active assets in the Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
Dexmedetomidine Medical College of Wisconsin | Phase 4 | BB |
Lidocaine Medical College of Wisconsin | Phase 4 | BB |
Relatlimab Bristol-Myers Squibb | Phase 2 | BB |
VITAMIN D Tanta University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Granulocyte Colony-Stimulating Factor Lenograstim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →